Two Sigma Advisers LP Acquires 153,300 Shares of Grifols SA, Barcelona (GRFS)

Two Sigma Advisers LP grew its holdings in Grifols SA, Barcelona (NASDAQ:GRFS) by 252.1% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 214,100 shares of the biotechnology company’s stock after acquiring an additional 153,300 shares during the period. Two Sigma Advisers LP’s holdings in Grifols SA, Barcelona were worth $4,907,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in GRFS. BNP Paribas Arbitrage SA grew its holdings in shares of Grifols SA, Barcelona by 7.9% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 31,440 shares of the biotechnology company’s stock worth $688,000 after purchasing an additional 2,300 shares during the last quarter. New York State Common Retirement Fund grew its holdings in shares of Grifols SA, Barcelona by 3.4% in the 3rd quarter. New York State Common Retirement Fund now owns 1,133,205 shares of the biotechnology company’s stock worth $24,806,000 after purchasing an additional 37,157 shares during the last quarter. Ameriprise Financial Inc. grew its holdings in shares of Grifols SA, Barcelona by 8.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 2,054,762 shares of the biotechnology company’s stock worth $44,958,000 after purchasing an additional 153,563 shares during the last quarter. Great West Life Assurance Co. Can grew its holdings in shares of Grifols SA, Barcelona by 6.6% in the 3rd quarter. Great West Life Assurance Co. Can now owns 445,901 shares of the biotechnology company’s stock worth $9,718,000 after purchasing an additional 27,470 shares during the last quarter. Finally, Citadel Advisors LLC bought a new stake in shares of Grifols SA, Barcelona in the 3rd quarter worth about $4,245,000. Institutional investors own 22.26% of the company’s stock.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ:GRFS opened at $21.20 on Friday. Grifols SA, Barcelona has a 12 month low of $18.11 and a 12 month high of $25.18. The company has a debt-to-equity ratio of 1.62, a quick ratio of 1.35 and a current ratio of 3.01. The stock has a market cap of $14,475.85, a price-to-earnings ratio of 19.27, a P/E/G ratio of 1.34 and a beta of 1.18.

Several equities research analysts have recently weighed in on GRFS shares. BidaskClub lowered shares of Grifols SA, Barcelona from a “buy” rating to a “hold” rating in a report on Saturday, January 20th. Morgan Stanley lowered their target price on shares of Grifols SA, Barcelona from $23.00 to $22.00 and set an “underweight” rating on the stock in a report on Thursday, March 1st. Zacks Investment Research raised shares of Grifols SA, Barcelona from a “hold” rating to a “buy” rating and set a $23.00 target price on the stock in a report on Thursday, March 22nd. ValuEngine raised shares of Grifols SA, Barcelona from a “hold” rating to a “buy” rating in a report on Friday, February 2nd. Finally, HSBC raised shares of Grifols SA, Barcelona from a “reduce” rating to a “hold” rating in a report on Wednesday, March 14th. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the company’s stock. Grifols SA, Barcelona presently has a consensus rating of “Hold” and a consensus price target of $22.50.

ILLEGAL ACTIVITY WARNING: “Two Sigma Advisers LP Acquires 153,300 Shares of Grifols SA, Barcelona (GRFS)” was published by WKRB News and is the property of of WKRB News. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.wkrb13.com/2018/03/31/two-sigma-advisers-lp-acquires-153300-shares-of-grifols-sa-barcelona-grfs.html.

Grifols SA, Barcelona Company Profile

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.

Want to see what other hedge funds are holding GRFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Grifols SA, Barcelona (NASDAQ:GRFS).

Institutional Ownership by Quarter for Grifols SA, Barcelona (NASDAQ:GRFS)

Receive News & Ratings for Grifols SA Barcelona Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols SA Barcelona and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply